...
首页> 外文期刊>Pharmacology & Pharmacy >Application of D-Optimal Study Design with Contour Surface Response for Designing Sustained Release Gliclazide Matrix Tablets
【24h】

Application of D-Optimal Study Design with Contour Surface Response for Designing Sustained Release Gliclazide Matrix Tablets

机译:具有轮廓表面响应的D-最优研究设计在格列齐特缓释片设计中的应用

获取原文
           

摘要

An optimized formulation of a sustained release tablet of Gliclazide was developed. The use of Doptimal design with a polynomial statistical model to analyze dissolution data reduced the number of laboratory tests required to obtain an optimal dosage form. The final formulation contained 22 mg of Methocel?E15LV, 16.5 mg Methocel?E15 and 10.0 mg of Dibasic Calcium Phosphate per 30 mg Gliclazide sustained release tablet. Dissolution studies performed on tablets from 5000 tablet test batches released greater than 90 percent of loaded drug in eight hours. Drug release from the optimized tablets followed a pattern more closely similar to zero-order than other mechanisms of drug release tested. Storage of tablets in accelerated and ambient conditions for 6 and 12 months respectively did not alter any of the physico-chemical properties, drug release or the drug release rate compared to initial observations and dissolution data of the prepared tablets. The addition of potassium phosphate and monosodium phosphate to the tablet reduced the effect pH has on Gliclazide dissolution compared to the commercially available product.
机译:开发了格列齐特缓释片剂的优化配方。使用具有多项式统计模型的Doptimal设计来分析溶出度数据可减少获得最佳剂型所需的实验室测试数量。最终制剂每30 mg格列齐特缓释片含22 mg的Methocel®E15LV,16.5 mg的Methocel®E15和10.0 mg的磷酸氢钙。在5000个片剂测试批次的片剂上进行的溶出度研究在8小时内释放了超过90%的载药量。从优化的药片中释放出来的药物比测试的其他药物释放机理更接近零阶。与制备的片剂的初步观察结果和溶出数据相比,将片剂在加速和环境条件下分别保存6个月和12个月不会改变任何理化性质,药物释放或药物释放速率。与市售产品相比,向片剂中添加磷酸钾和磷酸一钠可降低pH值对格列齐特溶解的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号